Key Highlights

  • CareDx shares are trading up 21.56% to $86.94, the largest gain among the five healthcare movers.
  • Acumen Pharmaceuticals shares are trading down 85.77% to $0.33 after its Phase 2 Alzheimer's trial missed its primary endpoint.
  • Regeneron Pharmaceuticals third-quarter Revenue rose 36% to $5.1 billion.
  • Alphatec Holdings now expects 2026 revenue near $862 million after a third-quarter shortfall.
  • The calculated spread between the best and worst move in this group is 107.33 percentage points.

Which Healthcare Stocks Are Moving the Most Today?

Healthcare shares were pulled in opposite directions on Oct 30, 2026, as quarterly reports and a failed Alzheimer's trial reset prices across five names. Regeneron Pharmaceuticals (NASDAQ:REGN) is trading up 14.21% at $935.14, and CareDx (NASDAQ:CDNA) is trading up 21.56% at $86.94, both after third-quarter results.

On the downside, Acumen Pharmaceuticals (NASDAQ:ABOS) is trading down 85.77% at $0.33 after its Phase 2 sabirnetug study missed its primary endpoint. ProMIS Neurosciences (NASDAQ:PMN) is trading down 42.60% at $6.36, with no company-specific announcement identified, and Alphatec Holdings (NASDAQ:ATEC) is trading down 34.04% at $7.50 after a third-quarter revenue shortfall and a lower full-year revenue outlook.

The stocks are presented in a fixed order rather than ranked by the size of the move, and each percentage is measured against that stock's own prior close. The sections below set out what each company has reported and flag where figures are dated, derived or unverified.

Regeneron Pharmaceuticals: Why Are Shares Trading Higher After Third-Quarter Results?

The biotechnology company reported third-quarter 2026 revenue up 36% to $5.1 billion, with non-GAAP Earnings of $20.07 per share, up 70%. EYLEA HD sales in the United States rose 62% to $699 million, although the wider U.S. EYLEA Franchise was flat at $1.1 billion because the original product declined.

Regeneron also disclosed a $1.0 billion upfront payment from Sanofi (NASDAQ:SNY) for four long-acting antibodies, with eligibility for up to $7.0 billion in further milestones. Cash and marketable securities were about $18.9 billion at September 30, 2026.

Market data from Oct 27, taken before the move, showed a market Capitalization of about $81.2 billion and a 52-week range of $575.93 to $859.34. Today's price sits above that high based on those figures, which may now be out of date.

Acumen Pharmaceuticals: What Happened When the ALTITUDE-AD Trial Missed Its Primary Endpoint?

The clinical-stage company said sabirnetug failed to beat placebo on the iADRS measure at 18 months at either the 35 mg/kg or 50 mg/kg dose in the 542-participant study. Key secondary endpoints, including CDR-SB, also missed statistical significance, and edema-type imaging abnormalities occurred in about 10% of treated participants.

Acumen said it will stop developing sabirnetug, plan cash conservation measures and evaluate strategic options, including its Enhanced Brain Delivery program. The prior close near $2.32 is derived from the percentage move rather than sourced.

Cash and marketable securities were $110.2 million at June 30, 2026, the latest figure available. Based on about 72.3 million shares, the calculated Market Value at $0.33 is roughly $24 million, well below that cash balance.

ProMIS Neurosciences: Is the Drop Linked to Acumen's Failed Alzheimer's Trial?

No ProMIS-specific announcement was identified for the decline, and the company's latest update was a chief commercial officer appointment earlier this month. The move did coincide with Acumen's report, and ProMIS's lead antibody, PMN310, also targets toxic amyloid Beta oligomers, but any link has not been confirmed.

ProMIS held $53.4 million in cash and short-term investments at June 30, 2026, up from $6.1 million at the end of 2025 after a January private Placement that raised $70.1 million net. The second-quarter net loss was $11.7 million.

The PRECISE-AD Phase 1b study enrolled 144 patients, and unblinded topline data are expected in the first quarter of 2027. The prior close near $11.08 is derived from the percentage move.

CareDx: How Big Was the Third-Quarter Beat and the Guidance Raise?

The transplant diagnostics company reported revenue up 39% to $139.4 million, led by Testing Services, which rose 65% to $119.2 million. Adjusted EBITDA doubled to $30.5 million from $15.3 million a year earlier, and GAAP Net Income reached $19.3 million.

Management lifted 2026 revenue guidance to $520 million to $530 million from $490 million to $500 million, and adjusted EBITDA guidance to $90 million to $100 million from $66 million to $78 million. Cash and equivalents stood at $250.5 million at September 30, 2026.

The quarter was the first to include a full period of Naveris, acquired on July 1, 2026, for $160 million in cash plus up to $100 million in contingent consideration. A market capitalization figure was not found.

Alphatec Holdings: Why Did Shares Slide Despite Higher EBITDA Guidance?

The spine-focused medical device company reported third-quarter revenue up 13% to $221 million, which management said fell short of its expectations, mainly because of lower Biologics attachment. Full-year revenue is now expected near $862 million, down from about $890 million in the February outlook, as reported by a third-party site.

Adjusted EBITDA for the quarter was $38 million, a 17.3% margin, and full-year adjusted EBITDA guidance moved up to about $137 million. Free Cash Flow is now guided to about $10 million, compared with at least $20 million previously.

The 52-week range of $6.82 to $23.29 comes from a data provider as of Oct 23 and may have changed, since the new price is close to the low end.

How the Moves Compare: A 107.33-Point Spread and a Negative Average

The five moves average a calculated negative 25.33%, pulled down by the Acumen decline. The calculated spread between the largest gain, CareDx at 21.56%, and the largest loss, Acumen at 85.77%, is 107.33 percentage points, and the calculated average absolute move is 39.64%.

The catalysts differ in kind: two quarterly beats with raised or expanded outlooks, one trial failure, one quarter with a shortfall and a trimmed revenue outlook, and one decline with no identified company announcement. The calculated price gap is also wide, with Regeneron at roughly 2,834 times the price of Acumen.

Prior closes for Acumen and ProMIS are derived from the percentage moves, and several market figures come from snapshots taken before today's trading, so the bases are not identical.

What to Watch Next: Regeneron Decisions, ProMIS Data and Biomarker Updates

Regeneron has several dated items: an FDA decision for cemdisiran is expected in November 2026, fuller data on its liver-fat therapy and Phase 2 results for baloncibart are due the same month, and a quarterly Dividend of $0.94 is payable on Dec 3, 2026. Target dates for Ordspono and Libtayo fall in February 2027 and March 2027.

ProMIS expects unblinded PRECISE-AD data in the first quarter of 2027. Acumen has promised additional biomarker and imaging data in the coming weeks, without a specific date, and has not disclosed a revised cash runway.

No dated release was identified for CareDx or Alphatec. CareDx plans an AlloHeme launch in the first quarter of 2027, and Alphatec investors will look to fourth-quarter results for any recovery in biologics attachment.